Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

291 views

Visitors from

US 53%·

AU 34%·

IN 7%·

GB 2%·

HK 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Cencora (COR) Reports Earnings Tomorrow: What To Expect

February 02, 2026 at 22:06 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

COR Cover Image

Healthcare distributor Cencora (NYSE: COR) will be reporting results this Wednesday before market open. Here’s what to look for.

Cencora beat analysts’ revenue expectations by 0.5% last quarter, reporting revenues of $83.73 billion, up 5.9% year on year. It was a satisfactory quarter for the company, with a narrow beat of analysts’ full-year EPS guidance estimates.

Is Cencora a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Cencora’s revenue to grow 6.1% year on year to $86.45 billion, slowing from the 12.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.03 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Cencora has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Cencora’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. UnitedHealth delivered year-on-year revenue growth of 12.3%, meeting analysts’ expectations, and Elevance Health reported revenues up 9.6%, falling short of estimates by 1.2%. UnitedHealth traded down 16.4% following the results while Elevance Health was up 7.5%.

Read our full analysis of UnitedHealth’s results here and Elevance Health’s results here.

Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices flat over the last month. Cencora is up 6.6% during the same time and is heading into earnings with an average analyst price target of $399.07 (compared to the current share price of $363.54).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article